Immatics (NASDAQ:IMTXW) Sees Significant Decrease in Short Interest

Immatics (NASDAQ:IMTXW) was the target of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,400 shares, a drop of 12.5% from the March 15th total of 1,600 shares. Based on an average trading volume of 4,000 shares, the short-interest ratio is presently 0.4 days.

Immatics Price Performance

NASDAQ:IMTXW opened at $2.70 on Tuesday. The business’s 50-day moving average is $3.28 and its two-hundred day moving average is $2.96. Immatics has a 12 month low of $1.39 and a 12 month high of $4.14.

Institutional Investors Weigh In On Immatics

Several hedge funds have recently modified their holdings of IMTXW. Virtu Financial LLC acquired a new position in Immatics in the 4th quarter worth $28,000. Jefferies Financial Group Inc. purchased a new stake in shares of Immatics during the fourth quarter worth about $80,000. JPMorgan Chase & Co. lifted its stake in shares of Immatics by 11.9% in the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock worth $1,293,000 after acquiring an additional 40,168 shares in the last quarter. Walleye Capital LLC boosted its holdings in Immatics by 25.7% in the second quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock valued at $889,000 after purchasing an additional 53,153 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in Immatics during the 4th quarter valued at approximately $529,000.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.